Adipocytokines as Pathogenic Mediators and Therapeutic Targets in Metabolic Syndrome-Related Cardiocerebrovascular Events
Current translational evidence is strongest for strategies targeting adiponectin/FGF21 signaling and IL-1/IL-6-related inflammatory pathways, while evidence for cerebrovascular outcomes remains limited, and adipokine-directed interventions remain promising but require rigorous clinical validation and disease-specific s...